Today: 11 June 2026
Browse Category

NYSE:JNJ 25 December 2025 - 6 January 2026

Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson shares fell 1.47% to $204.31 Monday, underperforming the S&P 500’s 0.64% gain. UBS reiterated a Buy rating but lowered earnings forecasts after management warned of about $0.20 adjusted EPS dilution from the Halda Therapeutics acquisition. J&J will present at the JPMorgan Healthcare Conference Jan. 12 and report Q4 results Jan. 21.
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

Johnson & Johnson shares dropped 2.2% to $202.86 Monday, underperforming a rising market as investors rotated out of healthcare stocks. The move comes ahead of key events including the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call. More than 67,000 talc lawsuits remain unresolved, with a special master set to review expert evidence in New Jersey federal court.
5 January 2026
···
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson shares closed up 0.02% at $206.95 on Wednesday, ahead of the New Year’s Day market holiday. The company completed its $3.05 billion acquisition of Halda Therapeutics and plans to appeal a $1.5 billion talc verdict. Drugmakers are set to raise list prices on at least 350 medicines in 2026, Reuters reported. J&J’s fourth-quarter earnings call is set for Jan. 21.
1 January 2026
·
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.
1 January 2026
··
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, adding the RIPTAC oncology platform and lead prostate cancer program. Shares slipped 0.3% to $206.91 in after-hours trading. The company expects about $0.20 dilution to adjusted EPS, split between 2025 and 2026, and will discuss 2026 guidance on its Jan. 21 earnings call.
31 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson has halted a Phase 2b trial of its experimental eczema drug JNJ-5939 after interim results failed to meet efficacy targets, though the therapy was well tolerated. The stock last traded near $207.63, slightly down before the market closed for the weekend. The New York Stock Exchange will reopen Monday.
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson shares closed at $207.63 Friday, down 0.07%, after the company halted a mid-stage trial of its eczema drug JNJ-5939 due to lack of efficacy. The drug was well-tolerated but failed to meet targets in interim analysis. JNJ’s market cap stands near $500 billion, with a 2.5% dividend yield. The stock traded at $207.86 after hours ahead of Monday’s market open.
27 December 2025
··
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

U.S. stock markets were closed Saturday after Wall Street ended Friday nearly flat; the Dow slipped 0.04%, S&P 500 fell 0.03%, and Nasdaq lost 0.09%. Large-cap healthcare stocks held steady, while biotech lagged. Johnson & Johnson halted a Phase 2 eczema drug trial after missing efficacy goals. Healthcare ETFs closed Friday with XLV at $156.05, XBI at $124.98, and IBB at $171.44.
27 December 2025
Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen Friday, Dec. 26, after the Christmas holiday. Johnson & Johnson shares last traded near $207.78, up 0.6% from the previous close, with recent sessions marked by low volume. The company faces renewed legal pressure after a Baltimore jury ordered it to pay over $1.5 billion in a talc case, with J&J planning to appeal. Over 67,000 talc-related lawsuits remain unresolved.
26 December 2025
·
Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson shares last closed at $207.78 on Dec. 24, up 0.97%, with after-hours trading nearly flat at $207.75 ahead of the Christmas market closure. The New York Stock Exchange was shut Dec. 25 and will reopen Dec. 26. J&J faces ongoing headline risk from talc litigation, including a recent $1.5 billion jury verdict in Baltimore. The company is appealing and disputes the claims.
25 December 2025
·
1 … 3 4 5 6 7 … 9

Stock Market Today

  • Soybean Prices Rise Amid Anticipation for WASDE Report and Weather Impact
    June 11, 2026, 4:58 AM EDT. Soybeans posted gains of 8 to 11 cents across most contracts on Wednesday, with the national average cash bean price rising 12 cents to $10.70 3/4. Soymeal and soy oil futures also experienced notable increases. Heavy precipitation is expected in key Midwestern states, potentially affecting crop conditions. Traders are awaiting Thursday's World Agricultural Supply and Demand Estimates (WASDE) report, forecasting steady carryout levels for old and new crop soybeans. July and August 2026 soybean futures rose over 10 cents, reflecting market optimism ahead of the report. The weather outlook and WASDE figures remain critical factors driving market activity in soybean trading.

Latest articles

Oracle Stock Moves Higher as AI Backlog Draws Focus

Oracle shares fall after data center spending outlook hits, even as cloud backlog hits new high

11 June 2026
Oracle shares plunged 8.9% in after-hours trading as investors balked at the company’s plan to raise about $40 billion in debt and equity to fund a massive AI data center buildout, despite record revenue and a $638 billion backlog; free cash flow was negative $23.7 billion in fiscal 2026 as capital spending soared, intensifying concerns over whether AI demand will translate into durable profit.
Nvidia Gets AI Approval From Apple But Shares Stay Flat

Nvidia’s $91 Billion Slide Leaves AI Stocks Facing Pressure

11 June 2026
Nvidia plunged 3.73% to $200.42 as investors questioned whether its $91 billion quarterly revenue outlook can withstand rising rates, inflation, and China export restrictions; the selloff hit AI and semiconductor stocks broadly, despite Nvidia’s record sales, making its next quarter’s results a critical test for sustaining its high valuation.
MoneySimpler Moves Into AI Crypto Trading Bots As Market Fills Up

MoneySimpler Moves Into AI Crypto Trading Bots As Market Fills Up

11 June 2026
MoneySimpler launches an AI-powered trading automation platform integrating crypto, forex, and equities for retail users without coding skills, as competition intensifies over dashboard features and AI capabilities; no audited returns or user data disclosed, leaving adoption and real-world performance uncertain.
Go toTop